Tyra Biosciences, Inc. (TYRA)
28.65
+3.79
(+15.25%)
USD |
NASDAQ |
Sep 04, 16:00
28.70
+0.05
(+0.17%)
After-Hours: 20:00
Tyra Biosciences Enterprise Value : 1.361B for Sept. 4, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 04, 2026 | 1.361B |
| September 03, 2026 | 1.135B |
| September 02, 2026 | 1.151B |
| September 01, 2026 | 1.161B |
| August 31, 2026 | 1.145B |
| August 28, 2026 | 1.140B |
| August 27, 2026 | 1.211B |
| August 26, 2026 | 1.216B |
| August 25, 2026 | 1.244B |
| August 24, 2026 | 1.208B |
| August 21, 2026 | 1.206B |
| August 20, 2026 | 1.184B |
| August 19, 2026 | 1.251B |
| August 18, 2026 | 1.205B |
| August 17, 2026 | 1.216B |
| August 14, 2026 | 1.160B |
| August 13, 2026 | 1.144B |
| August 12, 2026 | 1.161B |
| August 11, 2026 | 1.154B |
| August 10, 2026 | 1.218B |
| August 07, 2026 | 1.233B |
| August 06, 2026 | 1.260B |
| August 05, 2026 | 1.185B |
| August 04, 2026 | 1.592B |
| August 03, 2026 | 1.563B |
| Date | Value |
|---|---|
| July 31, 2026 | 1.554B |
| July 30, 2026 | 1.624B |
| July 29, 2026 | 1.508B |
| July 28, 2026 | 1.494B |
| July 27, 2026 | 1.505B |
| July 24, 2026 | 1.479B |
| July 23, 2026 | 1.489B |
| July 22, 2026 | 1.477B |
| July 21, 2026 | 1.552B |
| July 20, 2026 | 1.504B |
| July 17, 2026 | 1.568B |
| July 16, 2026 | 1.537B |
| July 15, 2026 | 1.583B |
| July 14, 2026 | 1.613B |
| July 13, 2026 | 1.601B |
| July 10, 2026 | 1.605B |
| July 09, 2026 | 1.621B |
| July 08, 2026 | 1.595B |
| July 07, 2026 | 1.557B |
| July 06, 2026 | 1.493B |
| July 02, 2026 | 1.478B |
| July 01, 2026 | 1.406B |
| June 30, 2026 | 1.557B |
| June 29, 2026 | 1.532B |
| June 26, 2026 | 1.518B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| CG Oncology, Inc. | 5.574B |
| Arrowhead Pharmaceuticals, Inc. | 11.96B |
| Oncolytics Biotech, Inc. | 101.43M |
| Sangamo Therapeutics, Inc. | 58.44M |
| Sarepta Therapeutics, Inc. | 2.634B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -45.56M |
| Total Expenses (Quarterly) | 45.56M |
| EPS Diluted (Quarterly) | -0.6904 |
| Earnings Yield | -8.35% |
| Normalized Earnings Yield | -8.352 |